サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1606457

糖尿病網膜症治療市場：糖尿病網膜症タイプ別、治療タイプ別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2024年～2032年

Diabetic Retinopathy Therapeutic Market, By Diabetic Retinopathy Type, By Treatment Type, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 303 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
糖尿病網膜症治療市場：糖尿病網膜症タイプ別、治療タイプ別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2024年～2032年
出版日: 2024年11月04日
発行: AnalystView Market Insights
ページ情報: 英文 303 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

糖尿病網膜症治療市場規模は2023年に91億932万米ドルとなり、2024年から2032年にかけてCAGR 6.88％で拡大

糖尿病網膜症治療市場-市場力学

糖尿病および糖尿病性網膜症の有病率の増加が市場需要を促進

世界の糖尿病罹患率の上昇により、糖尿病性網膜症を発症する人の数が増加しています。米国疾病予防管理センター（CDC）によると、2021年には米国の全年齢層で推定960万人が糖尿病性網膜症を患っています。しかし、治療レジメンの複雑さや治療の潜在的な副作用は、患者が処方された治療計画を守る意欲を失わせる可能性があります。それとは逆に、糖尿病網膜症の管理における継続的な調査と技術の進歩は、市場の成長を後押しすると期待されています。さらに、糖尿病患者の定期的な眼科検診の重要性に対する認識の高まりは、糖尿病網膜症治療市場の成長機会をもたらします。

糖尿病網膜症治療市場-主な洞察

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2024-2032年）に約6.88%のCAGRで毎年成長すると推定されます。

糖尿病網膜症タイプ別では、非増殖糖尿病網膜症が2023年に最大の市場シェアを示すと予測されました。

治療タイプ別では、2023年に抗血管内皮増殖因子（VGEF）薬が主要セグメントとなった。

地域別では、北米の糖尿病網膜症治療市場が2023年の主要収益源となった

糖尿病網膜症治療市場-セグメンテーション分析：

世界の糖尿病網膜症治療市場は、糖尿病網膜症タイプ、治療タイプ、エンドユーザー、地域に基づいてセグメント化されます。

糖尿病網膜症タイプ別では、増殖糖尿病網膜症と非増殖糖尿病網膜症の2つに分類されます。非増殖糖尿病網膜症分野が市場を独占しています。これは主に、糖尿病患者における有病率の高さ、早期発見・治療オプションの認知度・入手可能性の向上によるものです。

市場はエンドユーザー別では、眼科センター、病院、外来手術センター、その他の4つに分類されます。病院セクターが市場を独占しており、予測期間中もその優位性は維持されると思われます。この優位性は主に、糖尿病網膜症を効果的に管理するために不可欠な、高度な診断ツールや外科的介入を含む包括的なケアを提供する病院の能力によるものです。

糖尿病網膜症治療市場-地理的洞察

地理的に、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカの各地域に広がっています。これらの地域は、ビジネスをもたらす国によってさらに分けられます。

糖尿病網膜症治療市場-競合情勢：

糖尿病網膜症の有病率の増加は、革新的な治療戦略と包括的な患者ケアへの注力を特徴とする競合情勢を牽引しています。企業は、遠隔医療やデジタルヘルス・ソリューションなどの先進技術を活用し、患者のエンゲージメントを高め、治療へのアクセスを改善しています。さらに、糖尿病網膜症のさまざまな病期をターゲットとする新規治療法を導入するため、多くの組織が研究開発を優先し、アンメットメディカルニーズに対応しています。ヘルスケアプロバイダーや研究機関との連携やパートナーシップも一般的な戦略であり、これにより企業は市場へのリーチを拡大し、治療成果を向上させることができます。

目次

第1章 糖尿病網膜症治療市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 糖尿病網膜症治療の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 糖尿病網膜症治療産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 糖尿病網膜症治療市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 糖尿病網膜症治療市場情勢

  • 糖尿病網膜症治療市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 糖尿病網膜症治療市場- 糖尿病網膜症タイプ別

  • 概要
    • 糖尿病網膜症タイプ別：セグメントシェア分析
    • 増殖性糖尿病網膜症
    • 非増殖性糖尿病網膜症

第8章 糖尿病網膜症治療市場-治療タイプ別

  • 概要
    • 治療タイプ別：セグメントシェア分析
    • レーザー手術
    • 抗血管内皮増殖因子（VEGF）薬
    • 眼内ステロイド注射
    • 硝子体切除術

第9章 糖尿病網膜症治療市場- エンドユーザー別

  • 概要
    • エンドユーザー別：セグメントシェア分析
    • 眼科センター
    • 病院
    • 外来手術センター
    • その他

第10章 糖尿病網膜症治療市場-地域

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋地域
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析- 糖尿病網膜症治療業界

  • 競合ダッシュボード
    • Competitive Benchmarking
    • Competitive Positioning
  • 企業プロファイル
    • F. Hoffmann-La Roche Ltd.
    • Abbott
    • Alimera Sciences
    • Novartis AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Bayer AG
    • Oxurion NV
    • ABBVIE INC.
    • Sirnaomics
    • Ampio Pharmaceuticals Inc.
    • BCNPeptides
    • Genentech, Inc.
    • Kowa Company Ltd.
    • Aurobindo Pharma
    • Bausch Health Companies Inc.
    • Accord Healthcare
    • Regeneron Pharmaceuticals Inc.
    • Lumenis Be Ltd.
    • Glycadia, Inc.
    • Others

第12章 アナリストの全方位展望

目次
Product Code: ANV4172

REPORT HIGHLIGHT

Diabetic retinopathy therapeutic market size was valued at USD 9,109.32 Million in 2023, expanding at a CAGR of 6.88% from 2024 to 2032.

Diabetic retinopathy is a serious eye condition stemming from complications related to diabetes mellitus and is a leading cause of blindness worldwide. The severity of diabetic retinopathy depends on several factors, including the type of diabetes, the duration of the disease, and how well blood sugar levels are managed. Early symptoms may be minimal or even absent, but as the condition progresses, individuals can experience blurred vision, fluctuating eyesight, and impaired color perception, potentially leading to blindness if not addressed.

Diabetic Retinopathy Therapeutic Market- Market Dynamics

Increasing prevalence of diabetes and diabetic retinopathy to propel market demand

The rising incidence of diabetes globally has led to a higher number of individuals developing diabetic retinopathy. According to Centers for Disease Control and Prevention (CDC), an estimated 9.6 million people across all ages in the US were living with diabetic retinopathy in 2021.However, the complexity of treatment regimens and the potential side effects of therapies can discourage patients from adhering to their prescribed treatment plans. On the contrary, ongoing research and technological advancements in the management of diabetic retinopathy are expected to boost market growth. Furthermore, Increased awareness about the importance of regular eye examinations for diabetes patients presents an opportunity for growth in the diabetic retinopathy therapeutic market.

Diabetic Retinopathy Therapeutic Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.88% over the forecast period (2024-2032)

Based on diabetic retinopathy type segmentation, non-proliferative diabetic retinopathy was predicted to show maximum market share in the year 2023

Based on treatment type segmentation, anti-vascular endothelial growth factor (VGEF) drug was the leading segment in 2023

On the basis of region, The North America diabetic retinopathy therapeutic market was the leading revenue generator in 2023

Diabetic Retinopathy Therapeutic Market- Segmentation Analysis:

The Global Diabetic Retinopathy Therapeutic Market is segmented on the basis of Diabetic Retinopathy Type, Treatment Type, End user, and Region.

The market is divided into two categories based on diabetic retinopathy type: proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. The non-proliferative diabetic retinopathy sector dominates the market. This is mainly due to its higher prevalence among diabetic patients and the increasing awareness and availability of early detection and treatment options.

The market is divided into four categories based on end user: ophthalmic centers, hospitals, ambulatory surgery centers, and others. The hospitals sector dominates the market and is likely to maintain its dominance during the forecast period. This dominance is primarily driven by hospitals' ability to provide comprehensive care, including advanced diagnostic tools and surgical interventions, which are crucial for managing diabetic retinopathy effectively.

Diabetic Retinopathy Therapeutic Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Diabetic Retinopathy Therapeutic Market- Competitive Landscape:

The increasing prevalence of diabetic retinopathy is driving a competitive landscape characterized by innovative treatment strategies and a focus on comprehensive patient care. Companies are leveraging advanced technologies, such as telemedicine and digital health solutions, to enhance patient engagement and improve access to care. Additionally, many organizations are prioritizing research and development to introduce novel therapies that target various stages of diabetic retinopathy, thereby addressing unmet medical needs. Collaboration and partnerships with healthcare providers and research institutions are also common strategies, enabling companies to expand their market reach and improve treatment outcomes.

Recent Developments:

In April 2024, Ocular Therapeutix, Inc. announced promising topline results from its Phase 1 HELIOS study, which investigated AXPAXLI against a sham control in patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME). The study's positive findings highlight Ocular's commitment to developing innovative therapies for conditions like wet age-related macular degeneration and diabetic retinopathy.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • F. Hoffmann-La Roche Ltd.
  • Abbott
  • Alimera Sciences
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Bayer AG
  • Oxurion NV
  • ABBVIE INC.
  • Sirnaomics
  • Ampio Pharmaceuticals Inc.
  • BCNPeptides
  • Genentech, Inc.
  • Kowa Company Ltd.
  • Aurobindo Pharma
  • Bausch Health Companies Inc.
  • Accord Healthcare
  • Regeneron Pharmaceuticals Inc.
  • Lumenis Be Ltd.
  • Glycadia, Inc.
  • Others

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY DIABETIC RETINOPATHY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Proliferative Diabetic Retinopathy
  • Non-proliferative Diabetic Retinopathy

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Laser Surgery
  • Anti-vascular Endothelial Growth Factor (VEGF) Drug
  • Intraocular Steroid Injection
  • Vitrectomy

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Ophthalmic Centers
  • Hospitals
  • Ambulatory Surgery Centers
  • Others

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Diabetic Retinopathy Therapeutic Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Diabetic Retinopathy Therapeutic Market Snippet by Diabetic Retinopathy Type
    • 2.1.2. Diabetic Retinopathy Therapeutic Market Snippet by Treatment Type
    • 2.1.3. Diabetic Retinopathy Therapeutic Market Snippet by End User
    • 2.1.4. Diabetic Retinopathy Therapeutic Market Snippet by Country
    • 2.1.5. Diabetic Retinopathy Therapeutic Market Snippet by Region
  • 2.2. Competitive Insights

3. Diabetic Retinopathy Therapeutic Key Market Trends

  • 3.1. Diabetic Retinopathy Therapeutic Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Diabetic Retinopathy Therapeutic Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Diabetic Retinopathy Therapeutic Market Opportunities
  • 3.4. Diabetic Retinopathy Therapeutic Market Future Trends

4. Diabetic Retinopathy Therapeutic Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Diabetic Retinopathy Therapeutic Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Diabetic Retinopathy Therapeutic Market Landscape

  • 6.1. Diabetic Retinopathy Therapeutic Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Diabetic Retinopathy Therapeutic Market - By Diabetic Retinopathy Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Diabetic Retinopathy Type, 2023 & 2032 (%)
    • 7.1.2. Proliferative Diabetic Retinopathy
    • 7.1.3. Non-proliferative Diabetic Retinopathy

8. Diabetic Retinopathy Therapeutic Market - By Treatment Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment Type, 2023 & 2032 (%)
    • 8.1.2. Laser Surgery
    • 8.1.3. Anti-vascular Endothelial Growth Factor (VEGF) Drug
    • 8.1.4. Intraocular Steroid Injection
    • 8.1.5. Vitrectomy

9. Diabetic Retinopathy Therapeutic Market - By End User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
    • 9.1.2. Ophthalmic Centers
    • 9.1.3. Hospitals
    • 9.1.4. Ambulatory Surgery Centers
    • 9.1.5. Others

10. Diabetic Retinopathy Therapeutic Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Diabetic Retinopathy Therapeutic Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Diabetic Retinopathy Therapeutic Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Diabetic Retinopathy Therapeutic Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Diabetic Retinopathy Therapeutic Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Diabetic Retinopathy Therapeutic Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Diabetic Retinopathy Therapeutic Industry

  • 11.1. Competitive Dashboard
    • 11.1.1. Competitive Benchmarking
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. F. Hoffmann-La Roche Ltd.
    • 11.2.2. Abbott
    • 11.2.3. Alimera Sciences
    • 11.2.4. Novartis AG
    • 11.2.5. Pfizer Inc.
    • 11.2.6. Regeneron Pharmaceuticals, Inc.
    • 11.2.7. Bayer AG
    • 11.2.8. Oxurion NV
    • 11.2.9. ABBVIE INC.
    • 11.2.10. Sirnaomics
    • 11.2.11. Ampio Pharmaceuticals Inc.
    • 11.2.12. BCNPeptides
    • 11.2.13. Genentech, Inc.
    • 11.2.14. Kowa Company Ltd.
    • 11.2.15. Aurobindo Pharma
    • 11.2.16. Bausch Health Companies Inc.
    • 11.2.17. Accord Healthcare
    • 11.2.18. Regeneron Pharmaceuticals Inc.
    • 11.2.19. Lumenis Be Ltd.
    • 11.2.20. Glycadia, Inc.
    • 11.2.21. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us